Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 11/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.48 |
| ▸ | SRC | P12931 | 9/20 | 0.44 |
| ▸ | SYK | P43405 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453272 | 0.90 | BRAF (0.48) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL7070212 | 0.84 | MAPK14 (0.49) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL27578812 | 0.82 | MAPK14 (0.44) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL27559838 | 0.82 | MAPK14 (0.54) | BRAFRAF1GSK3AMAPK14 | |
| SCHEMBL4464303 | 0.80 | MAPK14 (0.42) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL6784615 | 0.79 | ABL1 (0.50) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL4464429 | 0.79 | PIK3CA (0.52) | GSK3A | |
| SCHEMBL4459778 | 0.79 | MAPK14 (0.44) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL4091655 | 0.78 | ABL1 (0.84) | BRAFABL1EGFRRAF1LYN | |
| SCHEMBL28747223 | 0.77 | CLK2 (0.49) | BRAFRAF1GSK3AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | BRAF 1286/4885ABL1 719/4885EGFR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.